Metrics as of 10/15/2026, 06:39 PM (Berlin time), refresh in progress.
Cognition Therapeutics Stock
Cognition Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Lisa Ricciardi
- Employees
- 14
- Market cap
- $69 M
- IPO
- 08/10/2021
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal…
Cognition Therapeutics stock: price history
1D
-6.7%
1W
-19.0%
1M
-29.6%
6M
-34.7%
YTD
-46.3%
1Y
-60.4%
2Y
+72.2%
5Y
-93.9%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~24% stronger price swings than usual
Ask the agents about Cognition Therapeutics
Analyst assessment of Cognition Therapeutics
PRICE TARGET LOW
US$3.00
CONSENSUS
US$3.00
MEDIAN
US$3.00
PRICE TARGET HIGH
US$3.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 27/03/2026
Cognition Therapeutics stock metrics
P/E
-3.79
P/B
2
EV/EBITDA
-2.16
RETURN ON EQUITY
-11.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.02
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.9%
FLOAT SHARES
87,384,205
AVG. DAILY VOLUME (30D)
521,859
Insider transactions (SEC)
RICHSTONE ELLEN B
Wallace Peggy
Monia Brett P
Khattar Jack A.
Fletcher Aaron G.L.
Institutional holders
Comparable stocks
Frequently asked questions about Cognition Therapeutics stock
What does Cognition Therapeutics do?
Cognition Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Lisa Ricciardi, the company employs around 14 people.
The IPO was on 08/10/2021; the stock trades on NASDAQ under the ticker CGTX.
What do analysts say about Cognition Therapeutics stock?
7 analysts rate the stock, the consensus is Buy (as of 27/03/2026).
The average price target is US$3.00, ranging from US$3.00 to US$3.00, with a median of US$3.00.
This is an external assessment, not a statement by Market Jury.
When does Cognition Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 24% stronger than usual.
Does Cognition Therapeutics pay a dividend?
No, Cognition Therapeutics currently does not pay a dividend.
Which stocks are comparable to Cognition Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Cognition Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Cognition Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.